"What a beautiful gift, life": Dignity therapy and the making of a legacy in a patient with grade 4 glioblastoma.

Palliat Support CareOct 26, 2026 (epub)

Francesca Sireci, Jessica Rossi, Anna Pisanello et al.

✦ AI-curated · Sources linked

Case in brief

A man in his mid-40s with grade 4 glioblastoma of the corpus callosum received psycho-oncological support from diagnosis, with parallel support for his caregiver. Dignity therapy was provided while his cognitive abilities were strongest, producing a book that he shared with several hundred people in his community. As callosal disconnection syndrome progressed, therapy shifted to embodied, musical, and relational approaches, sustaining psychological contact through the terminal phase. The report describes dignity therapy as feasible when introduced early and adapted as cognition declined.

What made this case unusual

The patient distributed his dignity-therapy document as a book to several hundred community members, extending the intervention into communal legacy work.

Diagnostic / clinical pearl

In glioblastoma with progressive cognitive decline, dignity therapy may be most feasible when offered during a period of maximal cognitive competence, with support adapted as communication changes.

Why it matters

The case illustrates that psychological support may continue beyond verbal communication through embodied, musical, and relational approaches.

Source

Published in Palliat Support Care. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.